Baseline Characteristics of the Intention-to-Treat Population
tumor
ONCOLOGY, TUMOR, LIVER METASTASES
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LM, liver metastases.Unless otherwise indicated, data are expressed as No. (%) of patients.Includes American Indian or Alaska Native, Black, Native Hawaiian or Other Pacific Islander, and unknown race or ethnicity.Scores range from 0 to 5, with lower scores indicating fewer restrictions in daily activity.Plasma tumor mutation burden was higher in patients with LM than in those without LM (median, 19.2 [IQR, 11.5-30.6] vs 12.3 [IQR, 7.7-20.6] mutations/Mb; Among patients randomized to BSC, the median OS was 3.61 (90% CI, 3.15-4.47) months for patients with LM and 4.98 (90% CI, 1.91-9.00) for patients without LM. For patients in the durvalumab plus tremelimumab group, the median OS was 5.39 (90% CI, 3.81-6.24) months for patients with LM and 9.43 (90% CI, 7.39-10.18) months for patients without LM (